Peelerubin8161

Despite advances in imaging diagnostic modalities, hepatocellular carcinoma is sometimes incidentally diagnosed on histological examination of the liver explant. Our objectives were 1) To compare the characteristics between incidental and known hepatocellular carcinoma and 2) To estimate survival and tumor recurrence after liver transplantation.

Retrospective, single-center study. The inclusion criteria were 1) cirrhotic patients, age≥18 years, 2) Liver transplantation between 1998 and 2018, and 3) hepatocellular carcinoma diagnosed on the histopathologic examination of the explanted liver. Cholangiocarcinoma and patients with early retransplantation were excluded. Multivariate analysis was performed using binomial logistic regression to assess the factors associated incidental hepatocellular carcinoma. Kaplan-Meier curves were plotted to explore the impact on overall survival and recurrence free survival.

269 patients were enrolled. The prevalence of incidental hepatocellular carcinoma was 4.18% (95% Ce-free survival, although there was no tumor recurrence in incidental hepatocellular carcinoma group.A previously healthy 40-year-old male was admitted with a 10-day history of abdominal distension. Physical examinations revealed bulging flanks with a fluid wave and positive shifting dullness signs.In number 1 of volume 113 of this journal, one important article was published that evaluated statistically significant association (p 100) and the histological diagnosis of gangrenous acute cholecystitis in patients with who underwent cholecystectomy (OR = 3,1).We present the case of an ex-smoker, 69-year-old man whose medical background includes hypertension, chronic renal failure, atrial fibrillation anticoagulation, and chronic lower limb arterial ischemia. He suffered from abdominal pain associated with nausea and vomiting after hemodialysis session. The analysis showed c-protein reactive of 7 mg/L, 14,500 leukocytes with neutrophilia and 2.8 lactate. A computerized axial tomography (CAT) scan was performed, it was reported portal pneumatosis and distal ileum segment with intestinal pneumatosis, compatible with non-occlusive mesenteric ischemia.Introduction Thiopurines are used as maintenance therapy in patients with ulcerative colitis (UC). There are contradictory results regarding the relationship between adherence to treatment and risk of relapse. Objectives To quantify and evaluate the trends in thiopurines prescription rates, and to determine the impact and risk factors of non-adherence. Methods Analytical, observational and retrospective study of UC patients, on thiopurines, included in the ENEIDA single-center registry from October 2017 to October 2019. We included adult patients under clinical remission at the beginning of the study on thiopurines maintenance treatment for at least 6 months before recruitment. Adherence was evaluated with an electronic pharmaceutical prescription system. Adherence was considered when 80% or more of the prescribed medication was dispensed at the pharmacy. this website Kaplan-Meier curves and a regression model were used to examine year-to-year treatment dispensation and identify factors associated to non-adherence. Results A total of 41 patients were included, of whom 71% were males with a mean age of 44 (14) and 26.8% were concomitantly managed with biological therapy. Overall, 22% were non-adherent to thiopurines. No predictive factors of non-adherence were identified. Adherence rate did not correlate with disease activity for two years follow-up (OR 1.6; 95CI =0.3-9.1). Left-sided colitis and concomitant biological treatment were related with disease relapses (p ≤0.01). Conclusion The adherence to thiopurines in UC patients is high (78%). Non-adherence is not related to clinical or pharmacological factors. Adherence rate was not associated with disease activity.

the impact of the COVID-19 pandemic has led to the interruption of most manometry or impedance-pH monitoring studies. The risk of restarting activities is unknown.

assess the risk of SARS-CoV-2 virus infection, both to patients and healthcare workers, in relation to esophageal and anorectal functional tests during the pandemic without protective measures.

a questionnaire was designed to determine whether patients and healthcare workers had COVID-19, confirmed by either a test or compatible symptoms, after functional studies were performed from January until March 2020.

the survey was answered by 263 (92.9 %) patients. Four (1.52 %) patients had confirmed COVID-19 in the two weeks after the functional test (adjusted rate 8.34 cases per 1,000 [95 % CI -0.06-16.74], OR 0.84 [95 % CI 0.83-0.85], p < 0.001) and no patient after anorectal manometry. Another five had only compatible symptoms, for a total of nine patients (3.42 %) (adjusted rate 27.50 cases/1,000 [95 % CI 7.27-47.74], OR 2.84 [95 % CI 2.81-2.87]). In the total study period, 18.25 % had confirmed COVID-19 or compatible symptoms. The average number of days between the procedure and the first day of symptoms was progressively shortened (January 56 days, February 33 days, March 10.5 days). Two of ten healthcare workers (20 %) had confirmed COVID-19.

the risk of COVID-19 infection when performing functional tests is low and more related to the evolution of the pandemic rather than to the procedure itself. The small number of healthcare workers included in the study does not allow a definitive conclusion to be drawn on their risk of infection.

the risk of COVID-19 infection when performing functional tests is low and more related to the evolution of the pandemic rather than to the procedure itself. The small number of healthcare workers included in the study does not allow a definitive conclusion to be drawn on their risk of infection.

The effectiveness of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) depends on the selection of suitable patients. The Six-and-twelve score" distinguishes three groups of ideal patients with different overall survival based on the sum of number and size of tumors. This may impact clinical practice and trials design. The aim of the study is to assess the reproducibility and the prognostic value of the model in western patients treated with Drug-Eluting Beads (DEB)-TACE.

observational, retrospective, unicentric study developed in consecutive compensated patients treated with DEB-TACE from October/2008 to October/2017. Exclusion criteria were Child-Pugh ≥ 8 and DEB-TACE used as a bridge to liver transplantation.

225 HCC consecutive patients were included, BCLC-0/A n=131 (single nodules > 5, n=29), BCLC-B n=94. The median overall survival (OS) was 27 months (95% CI 23.8-30.2). OS was different between BCLC-0/A vs B 30 vs 24 months (p= 0.03), Child-Pugh A5 vs A6-B7 30 vs 27 months (p= 0.